Page 34 - FLIPBOOK

Lower Odds of Cardiac Events for GnRH Antagonists versus

Agonists

▪ Data from VigiBase, the WHO database of

individual case safety reports, collecting data

from >130 countries on adverse drug

reactions (ADRs).

▪ 10 504 ADRs for agonists, and 1606 for

antagonists; 805 (7.7%) were cardiac-related

for agonists and 102 for antagonists (6.4%).
Time from initiation of therapy to onset of

ADR was >1 year (mean 541.9, standard

deviation 909.6).

▪ The majority of ADRs were severe (82.8%) and

20.2% of cardiac events resulted in death.

Number and odds of cardiac events in patients with prostate cancer
taking GnRH agonists or antagonists (degarelix). EBE reports the lower
th
(5 percentile) bounds of the posterior distribution of odds.

E. Blanchard Cone BJU Int. 2020 https://doi.org/10.1111/bju.15059